# CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)

> **NCT03163667** · PHASE2 · COMPLETED · sponsor: **Calithera Biosciences, Inc** · enrollment: 69 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Placebo
- **DRUG:** CB-839
- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT03163667
- **Lead sponsor:** Calithera Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-06
- **Primary completion:** 2019-04-26
- **Final completion:** 2020-06-01
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2022-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03163667

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03163667, "CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03163667. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*